The FDA has approved Miudella® (copper intrauterine system) for the prevention of pregnancy in females of reproductive potential for up to 3 years.

Patients previously hospitalized for COVID-19 have an increased risk of subsequent death or hospitalization for various organ disorders up to 30 months after discharge.

A scientific statement regarding pain and treatment considerations in patients with PAD has been published by the AHA.

In a groundbreaking series of surgeries, doctors at Duke Health have successfully performed the world’s first living mitral valve replacement.